Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpeedGel Rx is a prescription topical transdermal gel developed by Gensco Pharma for the relief of pain, inflammation, and bruising associated with musculoskeletal conditions, arthritis, and soft tissue injuries. It is formulated as a non-NSAID alternative, utilizing Gensco's patented Isopeutic Transdermal Technology to deliver a combination of 14 active homeopathic ingredients directly to affected tissues. Regulated under the Homeopathic Pharmacopeia of the United States (HPUS), the product contains botanical and mineral-derived components such as *Arnica montana*, *Echinacea*, and *Colchicinum*. SpeedGel Rx aims to provide localized analgesic and anti-inflammatory effects while minimizing the systemic side effects typically associated with oral therapies or topical NSAIDs. It is dispensed in a patented metered-dose (MDose) container to ensure precise application and consistent dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SpeedGel Rx.